Medicare AdvantagePrior AuthMedium impact
Eucrisa® (crisaborole) (Revised)
Humana·Dermatology, Pediatrics, Family Medicine·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Eucrisa® (crisaborole) topical ointment effective January 1, 2026. Four specific criteria must be met including diagnosis of mild to moderate atopic dermatitis with at least 5% body surface area affected and failed treatment with standard topical corticosteroids and calcineurin inhibitors.
Action Required
Before January 1, 2026: Billing team must update prior authorization requirements for Eucrisa (crisaborole) prescriptions for Humana Medicare Advantage members. Providers must document: (1) mild to moderate atopic dermatitis diagnosis, (2) at least 5% affected body surface area, (3) previous treatment/intolerance to topical corticosteroids (triamcinolone, mometasone, betamethasone, or clobetasol), and (4) previous treatment/intolerance to topical calcineurin inhibitors (except children under 2). Claims without prior authorization will be denied.